Effects of vitamin E on chronic hepatitis C genotype 3: A randomized, double-blind, placebo-controlled study

Journal of the Medical Association of Thailand

Volumn 97, Issue , 2014, Pages S31-S40

  Bunchorntavakul, Chalermrat ^a   Wootthananont, Thorntavach ^a   Atsawarungruangkit, Amporn ^a  

^a RANGSIT UNIVERSITY   (Thailand)

Author keywords

Alanine aminotransferase; Genotype 3; Hepatitis C Virus; Oxidative stress; Vitamin E

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA TOCOPHEROL; ASPARTATE AMINOTRANSFERASE; PLACEBO; ANTIOXIDANT;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALBUMIN BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS C; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; DYSLIPIDEMIA; FATTY LIVER; FEMALE; FOLLOW UP; HEPATITIS C VIRUS GENOTYPE 3; HUMAN; HYPERTENSION; LIMIT OF DETECTION; MALE; NONALCOHOLIC FATTY LIVER; OXIDATIVE STRESS; QUANTITATIVE ASSAY; RANDOMIZED CONTROLLED TRIAL; VIRAL CLEARANCE; BLOOD; ENZYMOLOGY; GENETICS; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; MIDDLE AGED; THAILAND; VIROLOGY;

ADULT; ALANINE TRANSAMINASE; ANTIOXIDANTS; DOUBLE-BLIND METHOD; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; MALE; MIDDLE AGED; OXIDATIVE STRESS; THAILAND; VITAMIN E;

EID: 84929048427     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Lavanchy D. Evolving epidemiology of hepatitis C virus. Clin Microbiol Infect 2011; 17: 107-15.
2. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49: 1335-74.
3. Choi J, Ou JH. Mechanisms of liver injury. III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006; 290: G847-51.
4. Farinati F, Cardin R, De Maria N, Della LG, Marafin C, Lecis E, et al. Iron storage, lipid peroxidation and glutathione turnover in chronic anti-HCV positive hepatitis. J Hepatol 1995; 22: 449-56.
5. Cardin R, Saccoccio G, Masutti F, Bellentani S, Farinati F, Tiribelli C. DNA oxidative damage in leukocytes correlates with the severity of HCV-related liver disease: validation in an open population study. J Hepatol 2001; 34: 587-92.
6. Farinati F, Cardin R, Bortolami M, Burra P, Russo FP, Rugge M, et al. Hepatitis C virus: from oxygen free radicals to hepatocellular carcinoma. J Viral Hepat 2007; 14: 821-9.
7. Koike K. Molecular basis of hepatitis C virus-associated hepatocarcinogenesis: lessons from animal model studies. Clin Gastroenterol Hepatol 2005; 3 (10 Suppl 2): S132-5.
8. Bjelakovic G, Gluud LL, Nikolova D, Bjelakovic M, Nagorni A, Gluud C. Meta-analysis: antioxidant supplements for liver diseases-the Cochrane Hepato-Biliary Group. Aliment Pharmacol Ther 2010; 32: 356-67.
9. Rambaldi A, Jacobs BP, Iaquinto G, Gluud C. Milk thistle for alcoholic and/or hepatitis B or C liver diseases-a systematic cochrane hepato-biliary group review with meta-analyses of randomized clinical trials. Am J Gastroenterol 2005; 100: 2583-91.
10. Sies H, Murphy ME. Role of tocopherols in the protection of biological systems against oxidative damage. J Photochem Photobiol B 1991; 8: 211-8.
11. von Herbay A, Stahl W, Niederau C, Sies H. Vitamin E improves the aminotransferase status of patients suffering from viral hepatitis C: a randomized, double-blind, placebo-controlled study. Free Radic Res 1997; 27: 599-605.
12. Sanyal AJ, Chalasani N, Kowdley KV, McCullough A, Diehl AM, Bass NM, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N Engl J Med 2010; 362: 1675-85.
13. Neuschwander-Tetri BA. Hepatic lipotoxicity and the pathogenesis of nonalcoholic steatohepatitis: the central role of nontriglyceride fatty acid metabolites. Hepatology 2010; 52: 774-88.
14. Del Campo JA, Romero-Gomez M. Steatosis and insulin resistance in hepatitis C: a way out for the virus? World J Gastroenterol 2009; 15: 5014-9.
15. WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004; 363: 157-63.
16. Bedossa P, Moucari R, Chelbi E, Asselah T, Paradis V, Vidaud M, et al. Evidence for a role of nonalcoholic steatohepatitis in hepatitis C: a prospective study. Hepatology 2007; 46: 80-7.
17. Chu CJ, Hung TH, Hwang SJ, Wang YJ, Yang CF, Lin HC, et al. Association of insulin resistance with hepatic steatosis and progression of fibrosis in Chinese patients with chronic hepatitis C. Hepatogastroenterology 2008; 55: 2157-61.
18. Lawson A. A comparison of the natural history and outcome of treatment for Asian and non-Asian hepatitis C-infected patients. J Viral Hepat 2011; 18: e270-7.
19. Forrester JE, Wang XD, Knox TA, Borek CG, Tang AM, Johnson EJ. Factors associated with serum retinol, alpha-tocopherol, carotenoids, and selenium in Hispanics with problems of HIV, chronic hepatitis C, and drug use. J Public Health Policy 2009; 30: 285-99.
20. von Herbay A, de Groot H, Hegi U, Stremmel W, Strohmeyer G, Sies H. Low vitamin E content in plasma of patients with alcoholic liver disease, hemochromatosis and Wilson's disease. J. Hepatol 1994; 20: 41-6.
21. Bonis PA, Ioannidis JP, Cappelleri JC, Kaplan MM, Lau J. Correlation of biochemical response to interferon alfa with histological improvement in hepatitis C: a meta-analysis of diagnostic test characteristics. Hepatology 1997; 26: 1035-44.
22. Carithers RL Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology 1997; 26 (3 Suppl 1): 83S-8S.
23. Shiffman ML, Hofmann CM, Thompson EB, Ferreira-Gonzalez A, Contos MJ, Koshy A, et al. Relationship between biochemical, virological, and histological response during interferon treatment of chronic hepatitis C. Hepatology 1997; 26: 780-5.
24. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G Goncales FL Jr, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002; 347: 75-82.
25. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
26. McHutchison JG, Gordon SC, Schiff ER, Shiffman ML, Lee WM, Rustgi VK, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998; 339: 1485-92.
27. Poynard T, Marcellin P, Lee SS, Niederau C, Minuk GS, Ideo G, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet 1998; 352: 1426-32.
28. Poynard T, McHutchison J, Davis GL, Esteban-Mur R, Goodman Z, Bedossa P, et al. Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C. Hepatology 2000; 32: 1131-7.